Ticagrelor Improves Peripheral Arterial Function in Patients with a Previous Acute Coronary Syndrome

Objective: The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS). Furthermore, ticagrelor inhibits adenosine reuptake and increases coronary flow reserve during adenosine infusion in man. We wanted to determine whether ticagrelor improves peripheral arterial function in patients with a previous ACS compared to patients treated with aspirin, clopidogrel, or prasugrel. Methods: 127 patients with a previous ACS (>3 months to <3 years ago) on maintenance dose of (1) no ADP blocker (n = 35); (2) clopidogrel 75 mg (n = 35); (3) prasugrel 10 mg (n = 32), or (4) ticagrelor 90 mg twice daily (n = 25) were evaluated with peripheral arterial tonometry after forearm ischemia. Results: Ticagrelor improves peripheral arterial function compared to the other groups [(1) controls 1.78 ± 0.53; (2) clopidogrel 1.78 ± 0.45; (3) prasugrel 1.64 ± 0.33, and (4) ticagrelor 2.25 ± 0.54 (means ± SD)] with a significance of p < 0.01 for ticagrelor versus no ADP blocker, p < 0.01 for ticagrelor versus clopidogrel, and p < 0.001 for ticagrelor versus prasugrel. There were fewer patients with endothelial dysfunction (<1.67 reactive hyperemia index) in the ticagrelor group (12%) compared to aspirin (51%), clopidogrel (46%), and prasugrel (53%) (p < 0.01). Conclusion: Treatment with ticagrelor improves peripheral endothelial function compared to no ADP blocker, clopidogrel, or prasugrel treatment.

[1]  J. Sidaway,et al.  Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model , 2012, Journal of cardiovascular pharmacology and therapeutics.

[2]  B. Olde,et al.  Ticagrelor induces adenosine triphosphate release from human red blood cells. , 2012, Biochemical and biophysical research communications.

[3]  K. Huber,et al.  Pharmacokinetic basis of the antiplatelet action of prasugrel , 2012, Fundamental & clinical pharmacology.

[4]  R. Karas,et al.  Peripheral augmentation index as a biomarker of vascular aging: an invasive hemodynamics approach , 2011, European Journal of Applied Physiology.

[5]  C. Cannon,et al.  Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). , 2011, The American journal of cardiology.

[6]  C. Cannon,et al.  Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. , 2011, European heart journal.

[7]  Kamlesh Kothawade,et al.  Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. , 2011, Current problems in cardiology.

[8]  P. Pais,et al.  The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. , 2011, Journal of the American College of Cardiology.

[9]  J. Nawarskas,et al.  Ticagrelor: a novel reversible oral antiplatelet agent. , 2011, Cardiology in review.

[10]  V. Pasceri,et al.  High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. , 2011, Journal of the American College of Cardiology.

[11]  P. Gurbel,et al.  Current options in oral antiplatelet strategies during percutaneous coronary interventions. , 2011, Reviews in cardiovascular medicine.

[12]  V. Pasceri,et al.  High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. , 2011, Journal of the American College of Cardiology.

[13]  M. Keltai,et al.  Coronary Heart Disease Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2010 .

[14]  M. Penn,et al.  Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model , 2010, Thrombosis and Haemostasis.

[15]  D. Erlinge,et al.  The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. , 2010, International journal of cardiology.

[16]  R. Rubinshtein,et al.  Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. , 2010, European heart journal.

[17]  N. Toma.  Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study. , 2010, Maedica.

[18]  T. Munzel,et al.  Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study , 2010, Clinical Research in Cardiology.

[19]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[20]  S. Agewall,et al.  Evaluation of endothelial function using finger plethysmography , 2009, Clinical physiology and functional imaging.

[21]  J. Sugawara,et al.  Interrelationships among noninvasive measures of postischemic macro- and microvascular reactivity. , 2008, Journal of applied physiology.

[22]  Ramachandran S Vasan,et al.  Cross-Sectional Relations of Digital Vascular Function to Cardiovascular Risk Factors in the Framingham Heart Study , 2008, Circulation.

[23]  U. Walter,et al.  A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. , 2008, Atherosclerosis.

[24]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[25]  G. Burnstock,et al.  P2 receptors in cardiovascular regulation and disease , 2008, Purinergic Signalling.

[26]  R. Karas,et al.  Assessment of peripheral vascular endothelial function in the ambulatory setting , 2007, Vascular medicine.

[27]  Marie Gerhard-Herman,et al.  Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. , 2006, Journal of applied physiology.

[28]  T. Meinertz,et al.  Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery Disease: Evidence for Antioxidant and Antiinflammatory Effects , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[29]  Amir Lerman,et al.  Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. , 2004, Journal of the American College of Cardiology.

[30]  D. Erlinge,et al.  ADP Receptor P2Y12 Is Expressed in Vascular Smooth Muscle Cells and Stimulates Contraction in Human Blood Vessels , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[31]  Ayan R Patel,et al.  Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. , 2003, American heart journal.

[32]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[33]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[34]  A. Yeung,et al.  Close relation of endothelial function in the human coronary and peripheral circulations. , 1995, Journal of the American College of Cardiology.